Abstract
Introduction: Expanded hemodialysis (HD using a medium cut-off dialyzer [HD + MCO]) provides comparable or better removal of various uremic toxins, particularly large middle-molecule uremic toxins, than post-dilution online hemodiafiltration (olHDF). Uremic toxin-removing effectiveness between HD + MCO and mixed-dilution olHDF, one of the currently most efficient olHDF modalities, has not been assessed. Method: This randomized controlled trial was conducted in 14 prevalent thrice-a-week HD patients with blood flow rate above 400 mL/min. The patients were randomized into two sequences of 2-week treatment periods of HD + MCO and later mixed-dilution olHDF or vice versa. The reduction ratio (RR) values of small-molecule as well as middle-molecule uremic toxins and protein-bound uremic toxins were measured at baseline and at the end of the treatment. Results: When compared with mixed-dilution olHDF, HD + MCO provided slightly lower β2M RR, but the value was still higher than 75%; showed similar κFLC RR, IS RR, and URR; and yielded significantly higher RR values of α1M (p < 0.001) and λFLC (p < 0.001). Despite higher albumin loss in HD + MCO, the serum albumin levels at the end of the study were comparable between both groups. Conclusion: Expanded HD (HD + MCO) provided similar effectiveness in removing various uremic toxins and could exhibit greater removal of large middle-molecule uremic toxins, such as α1M and λFLC. Expanded HD can be used as an effective alternative option for mixed-dilution olHDF.
References
1.
Glorieux
G
, Vanholder
R
. New uremic toxins: which solutes should be removed?
Contrib Nephrol
. 2011
;168
:117
–28
. .2.
Ronco
C
, Marchionna
N
, Brendolan
A
, Neri
M
, Lorenzin
A
, Martínez Rueda
AJ
. Expanded haemodialysis: from operational mechanism to clinical results
. Nephrol Dial Transpl
. 2018
;33
(Suppl 3
):iii41
–7
.3.
Masakane
I
, Sakurai
K
. Current approaches to middle molecule removal: room for innovation
. Nephrol Dial Transplant
. 2018
;33
(Suppl 3
):iii12
–21
. .4.
Ciceri
P
, Cozzolino
M
. Expanded haemodialysis as a current strategy to remove uremic toxins
. Toxins
. 2021
;13
(6
):380
. .5.
Barreto
FC
, Barreto
DV
, Canziani
MEF
. Uremia retention molecules and clinical outcomes
. Contrib Nephrol
. 2017
;191
:18
–31
. .6.
García-Prieto
A
, Vega
A
, Linares
T
, Abad
S
, Macías
N
, Aragoncillo
I
, Evaluation of the efficacy of a medium cut-off dialyser and comparison with other high-flux dialysers in conventional haemodialysis and online haemodiafiltration
. Clin Kidney J
. 2018
;11
:742
–6
.7.
Donati
G
, Moretti
MI
, Baraldi
O
, Spazzoli
A
, Capelli
I
, Comai
G
, Removal of free light chains in hemodialysis patients without multiple myeloma: a crossover comparison of three different dialyzers
. BMC Nephrol
. 2016
;17
:1
–9
.8.
Desjardins
L
, Liabeuf
S
, Lenglet
A
, Lemke
HD
, Vanholder
R
, Choukroun
G
, Association between free light chain levels, and disease progression and mortality in chronic kidney disease
. Toxins
. 2013
;5
(11
):2058
–73
.9.
Tiranathanagul
K
, Eiam-Ong
S
. High-efficiency hemodiafiltration
. In: Kargar
A
, editor. Aspects in dialysis
. UK
: IntechOpen London
; 2018
. p. 91
–107
.10.
Schiffi
H
. High-volume online hemodiafiltration treatment and outcome end-stage renal disease patients: more than one mode
. Int Urol Nephrol
. 2020
;58
:1501
–6
.11.
Ok
E
, Asci
G
, Toz
H
, Ok
ES
, Kircelli
F
, Yilmaz
M
, Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study
. Nephrol Dial Transpl
. 2013
;28
:192
–202
.12.
Canaud
B
, Bragg-Gresham
JL
, Marshall
MR
, Desmeules
S
, Gillespie
BW
, Depner
T
, Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS
. Kidney Int
. 2006
;69
:2087
–93
.13.
Pedrini
LA
, Wiesen
G
. Overcoming the limitations of post-dilution on-line hemodiafiltration: mixed dilution hemodiafiltration
. Contrib Nephrol
. 2011
;175
:129
–40
. .14.
Pedrini
LA
, Cristofaro
VD
. On-line mixed hemodiafiltration with a feedback for ultrafiltration control: effect on middle-molecule removal
. Kidney Int
. 2003
;64
:1505
–13
.15.
Feliciani
A
, Riva
MA
, Zerbi
S
, Ruggiero
P
, Plati
AR
, Cozzi
G
, New strategies in haemodiafiltration (HDF): prospective comparative analysis between on-line mixed HDF and mid-dilution HDF
. Nephrol Dial Transpl
. 2007
;22
(6
):1672
–9
.16.
Ciceri
P
, Tettamanti
G
, Galassi
A
, Magagnoli
L
, Fabresse
N
, Alvarez
JC
, Pro-calcifying analysis of uraemic serum from patients treated with medium cut-off membrane in a prospective, cross-over study
. Clin Kidney J
. 2021
;14
(7
):1798
–807
.17.
Storr
M
, Ward
RA
. Membrane innovation: closer to native kidneys
. Nephrol Dial Transplant
. 2018
;33
(Suppl 3
):iii22
–7
. .18.
Thammathiwat
T
, Tiranathanagul
K
, Limjariyakul
M
, Chariyavilaskul
P
, Takkavatakarn
K
, Susantitaphong
P
, Super high-flux hemodialysis provides comparable effectiveness with high-volume postdilution online hemodiafiltration in removing protein-bound and middle-molecule uremic toxins: a prospective cross-over randomized controlled trial
. Ther Apher Dial
. 2021
;25
:73
–81
.19.
Kirsch
AH
, Lyko
R
, Nilsson
LG
, Beck
W
, Amdahl
M
, Lechner
P
, Performance of hemodialysis with novel medium cut-off dialyzers
. Nephrol Dial Transpl
. 2017
;32
:165
–72
.20.
Reque
J
, Alba
AJ
, Panizo
N
, Sánchez-Canel
JJ
, Pascual
M
, Pons
PR
. Is expanded hemodialysis an option to online hemodiafiltration for small-and middle-sized molecules clearance?
Blood Purif
. 2019
;47
:126
–31
.21.
Maduell
F
, Rodas
L
, Broseta
JJ
, Gomez
M
, Xipell
M
, Guillen
E
, Medium cut-off dialyzer versus eight hemodiafiltration dialyzers: comparison using a global removal score
. Artif Organs
. 2019
;48
:167
–74
.22.
Belmouaz
M
, Diolez
J
, Bauwens
M
, Duthe
F
, Ecotiere
L
, Desport
E
, Comparison of hemodialysis with medium cut-off dialyzer and on-line hemodiafiltration on the removal of small and middle-sized molecules
. Clin Nephrol
. 2018
;89
:50
–6
.23.
Lornoy
W
, Becaus
I
, Billiouw
JM
, Sierens
L
, Malderen
PV
, D'Haenens
P
. On-line hemodiafiltration. Remarkable removal of β2-microglobulin. Long-term clinical observations
. Nephrol Dial Transpl
. 2000
;15
(Suppl 1
):49
–54
. .24.
Maduell
F
, Moreso
F
, Pons
M
, Ramos
R
, Mora-Macià
J
, Carreras
J
, High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients
. J Am Soc Nephrol
. 2013
;24
(3
):487
–97
.25.
Ronco
C
, Clark
W
. Factors affecting hemodialysis and peritoneal dialysis efficiency
. Semin Dial
. 2001
;14
(4
):257
–62
. .26.
Cohen
G
. Immunoglobulin light chains in uremia
. Kidney Int Suppl
. 2003
;84
:S15
–8
. .27.
Cohen
G
, Rudnicki
M
, Schmaldienst
S
, Hörl
WH
. Effect of dialysis on serum/plasma levels of free immunoglobulin light chains in end-stage renal disease patients
. Nephrol Dial Transplant
. 2002
;17
:879
–83
. .28.
Pedrini
LA
, Cristofaro
VD
, Pagliari
B
, Samà
F
. Mixed predilution and postdilution online hemodiafiltration compared with the traditional infusion modes
. Kidney Int
. 2000
;58
:2155
–65
.29.
Sequera-Ortiz
PD
, Sequera
PD
, Albalate-Ramón
M
, Albalate
M
, Pérez-García
R
, Corchete-Prats
E
, A comparison of the effectiveness of two online hemodiafiltration modalities: mixed versus post-dilution
. Nefrologia
. 2013
;33
(6
):779
–87
.30.
Pedrini
LA
, Zawada
AM
, Winter
AC
, Pham
J
, Klein
G
, Wolf
M
, Effect of high-volume online mixed-hemodiafiltration on anemia management in dialysis patients
. PLoS One
. 2019
;14
(2
):e0212795
.31.
Pedrini
LA
, Comelli
M
, Ruggiero
P
, Feliciani
A
, Manfrini
V
, Cozzi
G
, Mixed hemodiafiltration reduces erythropoiesis stimulating agents requirement in dialysis patients: a prospective randomized study
. J Nephrol
. 2020
;33
:1037
–48
.32.
Hadad-Arrascue
F
, Nilsson
LG
, Rivera
AS
, Bernardo
AA
, Cabezuelo Romero
JB
. Expanded hemodialysis as effective alternative to on-line hemodiafiltration: a randomized mid-term clinical trial
. Ther Apher Dial
. 2022 Feb
;26
(1
):37
–44
.33.
Zickler
D
, Schindler
R
, Willy
K
, Martus
P
, Pawlak
M
, Storr
M
, Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients: a randomized controlled clinical trial
. PLoS One
. 2017 Jan 13
;12
(1
):e0169024
.34.
Belmouaz
M
, Bauwens
M
, Hauet
T
, Bossard
V
, Jamet
P
, Joly
F
, Comparison of the removal of uraemic toxins with medium cut-off and high-flux dialysers: a randomized clinical trial
. Nephrol Dial Transplant
. 2020 Feb 1
;35
(2
):328
–35
.35.
Weiner
DE
, Falzon
L
, Skoufos
L
, Bernardo
A
, Beck
W
, Xiao
M
, Efficacy and safety of expanded hemodialysis with the Theranova 400 dialyzer: a randomized controlled trial
. Clin J Am Soc Nephrol
. 2020
;15
:1310
–9
.36.
Potier
J
, Le Roy
F
, Faucon
J
, Besselièvre
T
, Renaudineau
E
, Farquet
C
, Elevated removal of middle molecules without significant albumin loss with mixed-dilution hemodiafiltration for patients unable to provide sufficient blood flow rates
. Blood Purif
. 2013
;36
:78
–83
.37.
Willy
K
, Girndt
M
, Voelkl
J
, Fiedler
R
, Martus
P
, Storr
M
, Expanded hemodialysis therapy of chronic hemodialysis patients prevents calcification and apoptosis of vascular smooth muscle cells in vitro
. Blood Purif
. 2018
;45
:131
–8
.38.
Zickler
D
, Schindler
R
, Willy
K
, Martus
P
, Pawlak
M
, Storr
M
, Medium cut-off (MCO) membranes reduce inflammation in chronic dialysis patients: a randomized controlled clinical trial
. PLoS One
. 2017
;12
:e0169024
.39.
Florens
N
, Juillard
L
. Expanded hemodialysis: news from the field
. Nephrol Dial Transpl
. 2018 Oct
;33
(Suppl 3
):iii48
–52
.© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
